Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Weber

Showing results (221-230 of 341) with videos related to

Pageof 35
Sort By:
Journal of Special Operations Medicine : a Peer Reviewed Journal for SOF Medical Professionals|November 15, 2013
Management of Junctional Hemorrhage in Tactical Combat Casualty Care: TCCC Guidelines?Proposed Change 13-03Russ S Kotwal, Frank K Butler, Kirby Gross, et al.
The American Journal of Geriatric Cardiology|January 5, 2008
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapyWilliam C Cushman, Joel M Neutel, Elijah Saunders, et al.
Journal of Clinical Pharmacology|April 13, 2018
Cardiovascular Safety of the β<sub>3</sub> -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY TrialWilliam B White, Christopher Chapple, Christian Gratzke, et al.
Lancet (London, England)|September 15, 2009
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trialMichael A Weber, Henry Black, George Bakris, et al.
Journal of the American Society of Hypertension : JASH|April 20, 2010
Combination therapy in hypertensionAlan H Gradman, Jan N Basile, Barry L Carter, et al.
Journal of the American Heart Association|June 15, 2026
Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MEDDavid E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
Hypertension (Dallas, Tex. : 1979)|September 28, 2020
Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for HypertensionDavid E Kandzari, Felix Mahfoud, Deepak L Bhatt, et al.
Blood Pressure|October 30, 2015
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trialSverre E Kjeldsen, Eivind Berge, Sripal Bangalore, et al.
American Heart Journal|April 25, 2007
Outcome after out-of-hospital cardiac arrest in a physician-staffed emergency medical system according to the Utstein styleHeidi L Estner, Christian Günzel, Gjin Ndrepepa, et al.
Journal of Human Hypertension|March 24, 2022
Emerging Authors Program for Global Cardiovascular Disease Research-A collaboration of the U.S. Centers for Disease Control and Prevention, the Lancet Commission on Hypertension Group, Resolve to Save Lives, and the World Hypertension LeagueDinesh Neupane, Bethany Hall, Qaiser Mukhtar, et al.
Pageof 35

Showing results (221-230 of 341) with videos related to

Sort By:
Pageof 35
Journal of Special Operations Medicine : a Peer Reviewed Journal for SOF Medical Professionals|November 15, 2013
Management of Junctional Hemorrhage in Tactical Combat Casualty Care: TCCC Guidelines?Proposed Change 13-03Russ S Kotwal, Frank K Butler, Kirby Gross, et al.
The American Journal of Geriatric Cardiology|January 5, 2008
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapyWilliam C Cushman, Joel M Neutel, Elijah Saunders, et al.
Journal of Clinical Pharmacology|April 13, 2018
Cardiovascular Safety of the β<sub>3</sub> -Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY TrialWilliam B White, Christopher Chapple, Christian Gratzke, et al.
Lancet (London, England)|September 15, 2009
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trialMichael A Weber, Henry Black, George Bakris, et al.
Journal of the American Society of Hypertension : JASH|April 20, 2010
Combination therapy in hypertensionAlan H Gradman, Jan N Basile, Barry L Carter, et al.
Journal of the American Heart Association|June 15, 2026
Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MEDDavid E Kandzari, Felix Mahfoud, Raymond R Townsend, et al.
Hypertension (Dallas, Tex. : 1979)|September 28, 2020
Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for HypertensionDavid E Kandzari, Felix Mahfoud, Deepak L Bhatt, et al.
Blood Pressure|October 30, 2015
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trialSverre E Kjeldsen, Eivind Berge, Sripal Bangalore, et al.
American Heart Journal|April 25, 2007
Outcome after out-of-hospital cardiac arrest in a physician-staffed emergency medical system according to the Utstein styleHeidi L Estner, Christian Günzel, Gjin Ndrepepa, et al.
Journal of Human Hypertension|March 24, 2022
Emerging Authors Program for Global Cardiovascular Disease Research-A collaboration of the U.S. Centers for Disease Control and Prevention, the Lancet Commission on Hypertension Group, Resolve to Save Lives, and the World Hypertension LeagueDinesh Neupane, Bethany Hall, Qaiser Mukhtar, et al.
Pageof 35